EyePoint Pharmaceuticals Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 144

Employees

  • Stock Symbol
  • EYPT

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $6.50
  • (As of Friday Closing)

EyePoint Pharmaceuticals General Information

Description

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Contact Information

Formerly Known As
pSivida, pSivida Corp., pSivida LTD
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 480 Pleasant Street
  • Suite A-210
  • Watertown, MA 02472
  • United States
+1 (833)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 480 Pleasant Street
  • Suite A-210
  • Watertown, MA 02472
  • United States
+1 (833)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EyePoint Pharmaceuticals Stock Performance

As of 14-Feb-2025, EyePoint Pharmaceuticals’s stock price is $6.50. Its current market cap is $444M with 68.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.50 $6.31 $5.90 - $29.45 $444M 68.3M 914K -$1.99

EyePoint Pharmaceuticals Financials Summary

As of 30-Sep-2024, EyePoint Pharmaceuticals has a trailing 12-month revenue of $45.7M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 170,656 998,897 8,488 333,562
Revenue 45,713 46,018 41,404 36,939
EBITDA (115,784) (75,950) (98,750) (50,440)
Net Income (103,570) (70,795) (102,254) (58,417)
Total Assets 300,917 355,184 180,356 263,372
Total Debt 21,922 4,906 45,769 39,204
Public Fundamental Data provided by Morningstar, Inc. disclaimer

EyePoint Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EyePoint Pharmaceuticals‘s full profile, request access.

Request a free trial

EyePoint Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic pro
Drug Discovery
Watertown, MA
144 As of 2022

Basel, Switzerland
 

Toluca, Mexico
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EyePoint Pharmaceuticals Competitors (67)

One of EyePoint Pharmaceuticals’s 67 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Landsteiner Scientific Formerly PE-Backed Toluca, Mexico
Swedish Orphan Biovitrum Formerly VC-backed Stockholm, Sweden
Merck & Co. Corporation Rahway, NJ
Cipla Corporation Mumbai, India
You’re viewing 5 of 67 competitors. Get the full list »

EyePoint Pharmaceuticals Patents

EyePoint Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D1043969-S1 Ocular injector Active 20-Jan-2023
CA-222991-S Ocular injector Active 20-Jan-2023
AU-2023230976-A1 Continuous dosing regimen for treatment of a condition of the eye Pending 11-Mar-2022
AU-2023230975-A1 Method of preventing age-related macular degeneration by administering an ocular drug delivery insert Pending 11-Mar-2022
EP-4489749-A1 Method of preventing age-related macular degeneration by administering an ocular drug delivery insert Pending 11-Mar-2022 A61K31/404
To view EyePoint Pharmaceuticals’s complete patent history, request access »

EyePoint Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyePoint Pharmaceuticals Investments & Acquisitions (3)

EyePoint Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) for . The deal was made on 17-Aug-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) 17-Aug-2021 Corporate Asset Purchase Buildings and Property
Icon Bioscience 28-Mar-2018 Merger/Acquisition Biotechnology
Control Delivery Systems 30-Dec-2005 Merger/Acquisition Drug Delivery
To view EyePoint Pharmaceuticals’s complete investments and acquisitions history, request access »

EyePoint Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 28, 2023

39.07 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view EyePoint Pharmaceuticals’s complete esg history, request access »

EyePoint Pharmaceuticals FAQs

  • When was EyePoint Pharmaceuticals founded?

    EyePoint Pharmaceuticals was founded in 1987.

  • Where is EyePoint Pharmaceuticals headquartered?

    EyePoint Pharmaceuticals is headquartered in Watertown, MA.

  • What is the size of EyePoint Pharmaceuticals?

    EyePoint Pharmaceuticals has 144 total employees.

  • What industry is EyePoint Pharmaceuticals in?

    EyePoint Pharmaceuticals’s primary industry is Drug Discovery.

  • Is EyePoint Pharmaceuticals a private or public company?

    EyePoint Pharmaceuticals is a Public company.

  • What is EyePoint Pharmaceuticals’s stock symbol?

    The ticker symbol for EyePoint Pharmaceuticals is EYPT.

  • What is the current stock price of EyePoint Pharmaceuticals?

    As of 14-Feb-2025 the stock price of EyePoint Pharmaceuticals is $6.50.

  • What is the current market cap of EyePoint Pharmaceuticals?

    The current market capitalization of EyePoint Pharmaceuticals is $444M.

  • What is EyePoint Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for EyePoint Pharmaceuticals is $45.7M.

  • Who are EyePoint Pharmaceuticals’s competitors?

    Novartis, Landsteiner Scientific, Swedish Orphan Biovitrum, Merck & Co., and Cipla are some of the 67 competitors of EyePoint Pharmaceuticals.

  • What is EyePoint Pharmaceuticals’s annual earnings per share (EPS)?

    EyePoint Pharmaceuticals’s EPS for 12 months was -$1.99.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »